Sarepta Therapeutics
SRPT
132 hedge funds and large institutions have $680M invested in Sarepta Therapeutics in 2016 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 34 reducing their positions, and 40 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 34
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
2% more call options, than puts
Call options by funds: $86.6M | Put options by funds: $85.3M
13% less funds holding
Funds holding: 151 → 132 (-19)
38% less capital invested
Capital invested by funds: $1.1B → $680M (-$420M)
48% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 40
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$27.8M |
| 2 |
JG
Jefferies Group
New York
|
+$20.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
+$14.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12.4M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$32.4M |
| 2 |
Millennium Management
New York
|
-$15.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.88M |
| 4 |
Renaissance Technologies
New York
|
-$7.28M |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$5.37M |
SRPT Hedge Fund Activity: Q1 2016 in Review
132 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2016, worth a combined $680M — down 38% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of SRPT and 21 opened new positions — a net loss of 19 holders — while 34 trimmed existing stakes and 56 added.
The largest buyer was Perceptive Advisors, adding an estimated $27.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $32.4M sold.
- 132 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2016, down from 151 in Q4 2015.
- Funds reported $680M of Sarepta Therapeutics stock for Q1 2016, down 38% quarter-over-quarter.
- 21 funds opened new Sarepta Therapeutics positions in Q1 2016 and 40 closed out, a net change of -19 holders.
- The largest Sarepta Therapeutics buyer in Q1 2016 was Perceptive Advisors, an estimated $27.8M added.
- The largest Sarepta Therapeutics seller in Q1 2016 was Jennison Associates, an estimated $32.4M sold.
Based on aggregated 13F filings for Q1 2016.